Cited by 5,198PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Open access

Bryant, Helen E., Schultz, Niklas, Thomas, Huw D., Parker, Kayan M., Flower, Dan, Lopez, Elena, Kyle, Suzanne, Meuth, Mark, Curtin, Nicola J., Helleday, Thomas·2005·Nature

DOI 10.1038/nature03443

Open this paper in CoChat — free account

Abstract

Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.

Integrity signals

Registry

Crossref · 10.1038/nature03443

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
El‐Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 689
Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse
Murcia, J. M., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., Dantzer, F., Schreiber, V., Amé, J., Dierich, A., LeMeur, M., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 629
Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks
Lindahl, T. L., Satoh, M. S., Poirier, G. G., & Klungland, A. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89089-1 · Cited by 611
PARP is important for genomic stability but dispensable in apoptosisPreprint
Wang, Z., Stingl, L., Morrison, C. G., Jantsch, M. F., Łoś, M., Schulze‐Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557

Show all 26 references

Sorted by citations

Items 601–700 of 1,021

Validation and development of MTH1 inhibitors for treatment of cancer
Berglund, U. W., Sanjiv, K., Gad, H., Kalderén, C., Koolmeister, T., Pham, T. M., Göktürk, C., Jafari, R., Maddalo, G., Seashore-Ludlow, B. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw429 · Cited by 138
Self-citation
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Sen, T., Gay, C. M., & Byers, L. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.03 · Cited by 138
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 138
Genetic interactions of G-quadruplexes in humans
Zyner, K. G., Mulhearn, D. S., Adhikari, S., Cuesta, S. M., Antonio, M. D., Erard, N., Hannon, G. J., Tannahill, D., & Balasubramanian, S. (2019) · eLife · doi:10.7554/elife.46793 · Cited by 138
BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis
Foulkes, W. D. (2006) · Familial Cancer · doi:10.1007/s10689-005-2832-5 · Cited by 138
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
Domagała, P., Huzarski, T., Lubiński, J., Gugała, K., & Domagała, W. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1441-2 · Cited by 137
Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
Lesueur, P., Chevalier, F., Austry, J.-B., Waïssi, W., Burckel, H., Noël, G., Habrand, J., Saintigny, Y., & Joly, F. (2017) · Oncotarget · doi:10.18632/oncotarget.19079 · Cited by 137
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
Tsujino, T., Takai, T., Hinohara, K., Gui, F., Tsutsumi, T., Bai, X. F., Miao, C., Feng, C., Gui, B., Sztupinszki, Z. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35880-y · Cited by 137
Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets
Chalmers, A. J., Lakshman, M., Chan, N. H. L., & Bristow, R. G. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.06.001 · Cited by 136
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia
Liu, S. K., Coackley, C. L., Krause, M., Jalali, F., Chan, N. H. L., & Bristow, R. G. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.04.005 · Cited by 136
Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms
van den Tempel, N., Horsman, M. R., & Kanaar, R. (2016) · International Journal of Hyperthermia · doi:10.3109/02656736.2016.1157216 · Cited by 136
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Basourakos, S. P., Li, L., Aparicio, A. M., Corn, P. G., Kim, J., & Thompson, T. C. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666161214114948 · Cited by 136
TIRR regulates 53BP1 by masking its histone methyl-lysine binding function
Drané, P., Brault, M. E., Cui, G., Meghani, K. A., Chaubey, S., Detappe, A., Parnandi, N., He, Y. J., Zheng, X.-F., Botuyan, M. V., et al. (2017) · Nature · doi:10.1038/nature21358 · Cited by 136
Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy
Hengel, S. R., Spies, M., & Spies, M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.027 · Cited by 136
Disruption of Poly(ADP-ribosyl)ation Mechanisms Alters Responses of Arabidopsis to Biotic Stress
Adams-Phillips, L. C., Briggs, A. G., & Bent, A. F. (2009) · PLANT PHYSIOLOGY · doi:10.1104/pp.109.148049 · Cited by 136
The biological underpinnings of therapeutic resistance in pancreatic cancerPreprint
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 139
Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
Lupo, B., & Trusolino, L. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.004 · Cited by 135
Ubiquitinated-PCNA protects replication forks from DNA2-mediated degradation by regulating Okazaki fragment maturation and chromatin assembly
Thakar, T., Leung, W., Nicolae, C. M., Clements, K. E., Shen, B., Bielinsky, A., & Moldovan, G. (2020) · Nature Communications · doi:10.1038/s41467-020-16096-w · Cited by 135
Secondary mutations of BRCA1/2 and drug resistance
Dhillon, K. K., Swisher, E. M., & Taniguchi, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01840.x · Cited by 135
Timeless Interacts with PARP-1 to Promote Homologous Recombination Repair
Xie, S., Mortusewicz, O., Ma, H. T., Herr, P., Poon, R. Y. C., Helleday, T., & Qian, C. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.031 · Cited by 134
Self-citation
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers
Yap, T. A., Kristeleit, R. S., Michalarea, V., Pettitt, S. J., Lim, J. S. J., Carreira, S., Roda, D., Miller, R. E., Riisnaes, R., Miranda, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0163 · Cited by 134
Progress towards a clinically-successful ATR inhibitor for cancer therapy
Barnieh, F. M., Loadman, P. M., & Falconer, R. A. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100017 · Cited by 134
Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing
McManus, K. J., Barrett, I. J., Nouhi, Y., & Hieter, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813414106 · Cited by 133
The macro domain protein family: Structure, functions, and their potential therapeutic implications
Han, W., Li, X., & Fu, X. (2011) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2011.03.001 · Cited by 133
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
Ceccaldi, R., O’Connor, K. W., Mouw, K. W., Li, A. Y., Matulonis, U. A., D’Andrea, A. D., & Konstantinopoulos, P. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2593 · Cited by 133
BRCA1 gene: function and deficiency
Takaoka, M., & Miki, Y. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1182-2 · Cited by 133
Pleiotropic Cellular Functions of PARP1 in Longevity and Aging: Genome Maintenance Meets Inflammation
Mangerich, A., & Bürkle, A. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/321653 · Cited by 133
Functional Assays for Analysis of Variants of Uncertain Significance inBRCA2
Guidugli, L., Carreira, A., Caputo, S. M., Ehlén, Å., Galli, A., Monteiro, Á. N. A., Neuhausen, S. L., Hansen, T. V. O., Couch, F. J., & Vreeswijk, M. P. G. (2013) · Human Mutation · doi:10.1002/humu.22478 · Cited by 132
PARP inhibitors in ovarian cancer
Ledermann, J. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw094 · Cited by 132
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 132
Precision medicine: the foundation of future cancer therapeutics
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0016-z · Cited by 132
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA -Mutant Ovarian Cancer
Kummar, S., Oza, A. M., Fleming, G. F., Sullivan, D. M., Gandara, D. R., Naughton, M. J., Villalona-Calero, M. A., Morgan, R. J., Szabó, P., Youn, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2565 · Cited by 131
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme
Johannessen, T.-C. A., & Bjerkvig, R. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.37 · Cited by 131
DNA double-strand break repair pathways, chromosomal rearrangements and cancer
Kasparek, T., & Humphrey, T. C. (2011) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2011.10.007 · Cited by 131
MicroRNA-182-5p targets a network of genes involved in DNA repair
Krishnan, K., Steptoe, A. L., Martin, H. C., Wani, S., Nones, K., Waddell, N., Mariasegaram, M., Simpson, P. T., Lakhani, S. R., Gabrielli, B. G., et al. (2012) · RNA · doi:10.1261/rna.034926.112 · Cited by 131
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
Williamson, C. T., Kubota, E., Hamill, J. D., Klimowicz, A. C., Ye, R., Muzik, H., Dean, M. L., Tu, L., Gilley, D. P., Magliocco, A. M., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200229 · Cited by 131
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 131
Bridging of DNA breaks activates PARP2–HPF1 to modify chromatin
Bilokapić, S., Suskiewicz, M. J., Ahel, I., & Halić, M. (2020) · Nature · doi:10.1038/s41586-020-2725-7 · Cited by 131
The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cellsPreprint
Simoneau, A., Xiong, R., & Zou, L. (2021) · Genes & Development · doi:10.1101/gad.348479.121 · Cited by 131
The recognition and removal of cellular poly( ADP ‐ribose) signals
Barkauskaite, E., Jankevicius, G., Ladurner, A. G., Ahel, I., & Timinszky, G. (2013) · FEBS Journal · doi:10.1111/febs.12358 · Cited by 130
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Golan, T., Raitses‐Gurevich, M., Kelley, R. K., Bocobo, A. G., Borgida, A., Shroff, R. T., Holter, S., Gallinger, S., Ahn, D. H., Aderka, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0415 · Cited by 130
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
Makvandi, M., Pantel, A. R., Schwartz, L. E., Schubert, E. K., Xu, K., Hsieh, C., Hou, C., Kim, H., Weng, C.-C., Winters, H. D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97992 · Cited by 130
Base excision repair and its implications to cancer therapy
Grundy, G. J., & Parsons, J. L. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200013 · Cited by 130
Metastatic Triple-negative Breast Cancer
Rakha, E. A., & Chan, S. Y. T. (2011) · Clinical Oncology · doi:10.1016/j.clon.2011.03.013 · Cited by 130
Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
Liu, G., Yang, D., Rupaimoole, R., Pecot, C. V., Sun, Y., Mangala, L. S., Li, X., Ji, P., Cogdell, D. E., Hu, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv108 · Cited by 129
Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair
Löser, D. A., Shibata, A., Shibata, A., Woodbine, L. J., Jeggo, P. A., & Chalmers, A. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1027 · Cited by 129
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E. J., Middleton, M. R., Friedlander, M. L., Gourley, C., Plummer, R., Rustin, G. J. S., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0435-8 · Cited by 129
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Boussios, S., Karihtala, P., Moschetta, M., Karathanasi, A., Sadauskaite, A., Rassy, E., & Pavlidis, N. A. (2019) · Diagnostics · doi:10.3390/diagnostics9030087 · Cited by 129
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
Shenoy, T., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx165 · Cited by 128
Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer
Tello‐Lafoz, M., Srpan, K., Sanchez, E. E., Hu, J. Y., Remšík, J., Romin, Y., Calò, A., Hoen, D. R., Bhanot, U. K., Morris, L. G. T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.020 · Cited by 129
REV1 and polymerase ζ facilitate homologous recombination repair
Sharma, S., Hicks, J. K., Chute, C. L., Brennan, J. R., Ahn, J.-Y., Glover, T. W., & Canman, C. E. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr769 · Cited by 127
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
Mirza, M. R., Pignata, S., & Ledermann, J. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy174 · Cited by 127
c-MYC-Induced Genomic InstabilityPreprint
Kuzyk, R., & Mai, S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014373 · Cited by 127
Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics
Larsen, M. J., Thomassen, M., Gerdes, A., & Kruse, T. A. (2014) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s18715 · Cited by 126
Role of PARP Inhibitors in Cancer Biology and Therapy
Davar, D., Beumer, J. H., Hamieh, L., & Tawbi, H. A.-H. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802002464 · Cited by 126
N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide
Tang, J.-B., Svilar, D., Trivedi, R. N., Wang, X., Goellner, E. M., Moore, B., Hamilton, R. L., Banze, L. A., Brown, A. R., & Sobol, R. W. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor011 · Cited by 126
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
Pulliam, N., Fang, F., Özeş, A., Tang, J., Adewuyi, A., Keer, H. N., Lyons, J. F., Baylin, S. B., Matei, D. E., Nakshatri, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0204 · Cited by 126
Mechanism-based design of agents that selectively target drug-resistant glioma
Lin, K., Gueble, S. E., Sundaram, R. K., Huseman, E. D., Bindra, R. S., & Herzon, S. B. (2022) · Science · doi:10.1126/science.abn7570 · Cited by 126
Involvement of Polynucleotide Kinase in a Poly(ADP-ribose) Polymerase-1-dependent DNA Double-strand Breaks Rejoining Pathway
Audebert, M., Salles, B., Weinfeld, M., & Calsou, P. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.028 · Cited by 126
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
Kubota, E., Williamson, C. T., Ye, R., Elegbede, A. A., Peterson, L., Lees‐Miller, S. P., & Bebb, D. G. (2014) · Cell Cycle · doi:10.4161/cc.29212 · Cited by 125
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
Dean, E. J., Middleton, M. R., Pwint, T. P., Swaisland, H., Carmichael, J., Goodege, P., & Ranson, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.555 · Cited by 125
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
Wang, C., Jette, N., Moussienko, D., Bebb, D. G., & Lees‐Miller, S. P. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.01.007 · Cited by 125
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
Cheng, B., Pan, W., Xing, Y., Xiao, Y., Chen, J., & Xu, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114109 · Cited by 125
Sensitivity to Poly(ADP-ribose) Polymerase (PARP) Inhibition Identifies Ubiquitin-specific Peptidase 11 (USP11) as a Regulator of DNA Double-strand Break Repair
Wiltshire, T. D., Lovejoy, C. A., Wang, T., Xia, F., O’Connor, M. J., & Cortez, D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.104745 · Cited by 124
The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives
Gagné, J., Hendzel, M. J., Droit, A., & Poirier, G. G. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.02.013 · Cited by 124
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
Sandhu, S. K., Yap, T. A., & Bono, J. S. D. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.10.021 · Cited by 123
CtIP-mediated resection is essential for viability and can operate independently of BRCA1
Polato, F., Callén, E., Wong, N., Faryabi, R. B., Bunting, S. F., Chen, H. T., Kozak, M., Kruhlak, M. J., Reczek, C. R., Lee, W., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131939 · Cited by 123
Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising
Jekimovs, C., Bolderson, E., Suraweera, A., Adams, M. N., O'Byrne, K. J., & Richard, D. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00086 · Cited by 123
Update on PARP Inhibitors in Breast Cancer
Zimmer, A. S., Gillard, M., Lipkowitz, S., & Lee, J. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0540-2 · Cited by 123
Development of synthetic lethality in cancer: molecular and cellular classification
Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 123
Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)
Manjunath, M., & Choudhary, B. (2021) · Oncology Letters · doi:10.3892/ol.2021.12773 · Cited by 123
Synthesis, Biological Evaluation, and Structure–Activity Relationships of a Novel Class of Apurinic/Apyrimidinic Endonuclease 1 Inhibitors
Rai, G., Vyjayanti, V. N., Dorjsuren, D. G., Simeonov, A. M., Jadhav, A., Wilson, D. M., & Maloney, D. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201537d · Cited by 123
“Contextual” Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
Chan, N. H. L., & Bristow, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0527 · Cited by 123
Targeting DNA repair mechanisms in cancer
Furgason, J. M., & Bahassi, E. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.009 · Cited by 122
Chemotherapy and signaling
Bagnyukova, T., Serebriiskii, I. G., Zhou, Y., Hopper-Borge, E. A., Golemis, E. A., & Astsaturov, I. A. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.9.13738 · Cited by 122
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Smith, M. A., Reynolds, C. P., Kang, M. H., Kolb, E. A., Gorlick, R. G., Carol, H., Lock, R. B., Keir, S. T., Maris, J. M., Billups, C. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2572 · Cited by 122
PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells
Chatterjee, P., Choudhary, G. S., Sharma, A., Singh, K., Heston, W. D. W., Ciezki, J. P., Klein, E. A., & Almasan, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060408 · Cited by 122
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
Kim, D., & Nam, H. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158412 · Cited by 122
DNA Double Strand Break Repair: A Radiation Perspective
Kavanagh, J. N., Redmond, K. M., Schettino, G., & Prise, K. M. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5151 · Cited by 122
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Adam, S., Rossi, S. E., Moatti, N., De Marco Zompit, M., Xue, Y., Ng, T. F., Álvarez-Quilón, A., Desjardins, J., Bhaskaran, V., Martino, G., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00266-w · Cited by 121
The biological effects and clinical implications of BRCA mutations: where do we go from here?
Stoppa‐Lyonnet, D. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2016.93 · Cited by 121
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
YAMAGUCHI, H., Du, Y., Nakai, K., Ding, M., Chang, S. H., Hsu, J. L., Yao, J., Wei, Y., Nie, L., Jiao, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.311 · Cited by 121
The roles of RNA in DNA double-strand break repair
Bader, A. S., Hawley, B. R., Wilczynska, A., & Bushell, M. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0624-1 · Cited by 121
Inhibitors of PARP: Number crunching and structure gazing
Rudolph, J., Jung, K., & Luger, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121979119 · Cited by 121
Structure-Based DNA-Targeting Strategies with Small Molecule Ligands for Drug Discovery
Sheng, J., Gan, J., & Huang, Z. (2013) · Medicinal Research Reviews · doi:10.1002/med.21278 · Cited by 121
The Ku-dependent non-homologous end-joining but not other repair pathway is inhibited by high linear energy transfer ionizing radiation
Wang, H., Wang, X., Zhang, P., & Wang, Y. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.01.010 · Cited by 121
Inherited pancreatic cancer syndromes
Solomon, S., Das, S., Brand, R., & Whitcomb, D. C. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318278c4a6 · Cited by 120
Allicin Induces p53-Mediated Autophagy in Hep G2 Human Liver Cancer Cells
Chu, Y., Ho, C., Chung, J., Raghu, R., & Sheen, L. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf301298y · Cited by 120
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J. A., Barretina, J., & Tabernero, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 120
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Yuan, Y., Liao, Y.-M., Hsueh, C.-T., & Mirshahidi, H. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-16 · Cited by 120
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Bryant, C., Rawlinson, R., & Massey, A. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-570 · Cited by 119
Links between genome integrity and BRCA1 tumor suppression
Covington, M. L., & Greenberg, R. A. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.06.007 · Cited by 119
Cell Cycle–Targeted Cancer Therapies
Sherr, C. J., & Bártek, J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-040716-075628 · Cited by 119
Triple negative breast cancer: approved treatment options and their mechanisms of action
Mandapati, A., & Lukong, K. E. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04189-6 · Cited by 119
Emerging cancer therapeutic opportunities target DNA-repair systems
Ding, J., Miao, Z., Meng, L., & Geng, M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.04.007 · Cited by 119
RETRACTION: XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA damage
Lévy, N., Martz, A., Bresson, A., Spenlehauer, C., de MURCIA, G., & Murcia, J. M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj409 · Cited by 119
Retracted
Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery
Murphy, A., Fitzgerald, M., Ro, T., Kim, J. H., Rabinowitsch, A. I., Chowdhury, D., Schildkraut, C. L., & Borowiec, J. A. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201404111 · Cited by 118
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Schmid, S., Omlin, A. G., Higano, C. S., Sweeney, C. J., Chanzá, N. M., Mehra, N., Kuppen, M. C. P., Beltran, H., Conteduca, V., de Almeida, D. V. P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.21692 · Cited by 118
Identifying druggable disease-modifying gene products
Dixon, S. J., & Stockwell, B. R. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.08.003 · Cited by 118
Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining
Soni, A., Siemann, M., Grabos, M., Murmann-Konda, T., Pantelias, G. E., & Iliakis, G. E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku298 · Cited by 117

Authors: Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T.
Affiliations: University of Sheffield (GB)
Stockholm University (SE)
Newcastle University (GB)
Corresponding author: Helleday, Thomas
ORCID: Bryant, Helen E.
Thomas, Huw D.
Curtin, Nicola J.
Helleday, Thomas
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2005-04-14
Volume: 434
Issue: 7035
Pages: 913-917
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature03443
OpenAlex: W2009007206
Cited by: 5,198
References: 26
Citations by year: 2026: 213 · 2025: 256 · 2024: 286 · 2023: 355 · 2022: 355 · 2021: 396 · 2020: 388 · 2019: 282 · 2018: 290 · 2017: 273 · 2016: 265 · 2015: 230 · 2014: 243 · 2013: 223 · 2012: 213
FWCI: 56.59
Type: journal article
Language: en
Update notices: erratum (2007-05-17)
Open access: green
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Cancer Institute (F31CA260794)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, BRCA2 deficiency, homologous recombination, synthetic lethality, breast cancer, PARP1, DNA repair, replication fork collapse, single-strand breaks, γH2AX foci, RAD51 foci, base excision repair
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Benzodiazepines, DNA Damage, DNA Repair, DNA Replication, Mice, Nude, Neoplasms, Poly(ADP-ribose) Polymerases, Xenograft Model Antitumor Assays, Genes, BRCA2, BRCA2 Protein, Cell Line, Tumor, Mice, Azulenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks